Chimerix (NASDAQ:CMRX) Given Outperform Rating at Wedbush

Chimerix (NASDAQ:CMRX)‘s stock had its “outperform” rating reissued by equities research analysts at Wedbush in a report released on Monday, Marketbeat reports. They presently have a $6.00 target price on the biopharmaceutical company’s stock.

CMRX has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Chimerix in a research note on Monday, November 11th. StockNews.com upgraded Chimerix from a “sell” rating to a “hold” rating in a research report on Wednesday, August 21st.

Chimerix Stock Up 4.0 %

NASDAQ:CMRX traded up $0.03 during trading hours on Monday, hitting $0.89. 101,983 shares of the stock were exchanged, compared to its average volume of 353,981. The company’s 50 day moving average is $0.90 and its two-hundred day moving average is $0.91. The company has a market capitalization of $80.47 million, a P/E ratio of -0.96 and a beta of 1.13. Chimerix has a twelve month low of $0.75 and a twelve month high of $1.30.

Hedge Funds Weigh In On Chimerix

A number of large investors have recently bought and sold shares of CMRX. Valeo Financial Advisors LLC grew its position in Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 69,505 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Chimerix during the 2nd quarter worth about $137,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after acquiring an additional 138,098 shares in the last quarter. Finally, Acadian Asset Management LLC raised its holdings in Chimerix by 15.5% during the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock worth $2,304,000 after acquiring an additional 291,981 shares in the last quarter. Institutional investors and hedge funds own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.